Tirzepatide

Glycemic regulation, appetite, body weight, and cardiometabolic outcomes

Dual GIP/GLP-1 receptor agonist peptide

Tirzepatide is an FDA-approved active ingredient in Mounjaro and Zepbound; Apex material is RUO and is not the approved drug product

Overview

Tirzepatide is a peptide engineered to activate both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual-incretin design has been extensively studied in type 2 diabetes, chronic weight management, obstructive sleep apnea associated with obesity, and broader cardiometabolic research. It influences glucose-dependent insulin signaling, glucagon regulation, appetite pathways, and gastrointestinal motility. FDA approvals belong to specific prescription products and indications, not to separately supplied research material.

How it works

checkCreated with Sketch.

GIP receptor signaling: Adds glucose-dependent insulinotropic and metabolic signaling through the GIP pathway.

checkCreated with Sketch.

GLP-1 receptor signaling: Affects insulin/glucagon balance, appetite, satiety, and gastrointestinal signaling.

checkCreated with Sketch.

Integrated metabolic effects: Dual activation produces coordinated endocrine and central effects studied across large clinical programs.

Research areas

checkCreated with Sketch.

Type 2 diabetes

checkCreated with Sketch.

Chronic weight management

checkCreated with Sketch.

Obesity-related sleep apnea

checkCreated with Sketch.

Cardiometabolic outcomes

Research / study context

one

SURPASS program: Large randomized diabetes trials evaluated glycemic control, body weight, and safety.

two

SURMOUNT program: Obesity trials evaluated body weight, cardiometabolic risk markers, and obesity-related conditions.

Key research findings

checkCreated with Sketch.

Tirzepatide has a large human clinical evidence base.

checkCreated with Sketch.

Adverse effects and contraindications are product- and indication-specific.

checkCreated with Sketch.

Apex RUO material must not be marketed as Mounjaro, Zepbound, or a substitute for them.

Scientific reference starter set

one

Peptide Education Hub: Tirzepatide profile

two

PubMed: SURMOUNT-1 tirzepatide obesity

three

FDA prescribing information: Mounjaro / Zepbound

Research material

View available specifications and batch documentation in the Apex catalog.

Important

For research use only. Not for human consumption. This profile is educational and does not provide treatment or personal-use instructions.